|
|||||
|
|
Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors |
|
| Authors: | Mark A. Seefeld Meagan B. Rouse Kenneth C. McNulty Lihui Sun Jizhou Wang Dennis S. Yamashita Juan I. Luengo ShuYun Zhang Elisabeth A. Minthorn Nestor O. Concha Dirk A. Heerding |
| Affiliation: | 1. Oncology Chemistry, GlaxoSmithKline, Collegeville, PA 19426, USA;2. Oncology Biology, GlaxoSmithKline, Collegeville, PA 19426, USA;3. Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Collegeville, PA 19426, USA;4. Computational, Analytical and Structural Sciences, GlaxoSmithKline, Collegeville, PA 19426, USA |
| Abstract: | A pyrrolopyridinyl thiophene carboxamide 7 was discovered as a tractable starting point for a lead optimization effort in an AKT kinase inhibition program. SAR studies aided by a co-crystal structure of 7 in AKT2 led to the identification of AKT inhibitors with subnanomolar potency. Representative compounds showed antiproliferative activity as well as inhibition of phosphorylation of the downstream target GSK3β. |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |